Loading...
•
Sep 30, 2022
Enanta Pharmaceuticals Q4 2022 Earnings Report
Enanta Pharmaceuticals reported financial results for the fourth quarter of fiscal year 2022.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $20.3 million for the quarter, consisting of royalty revenue. The company's net loss was $26.3 million, or $1.27 per diluted common share. Enanta's cash, cash equivalents and marketable securities totaled $278.5 million at September 30, 2022.
Initiated a Phase 2 study of EDP-235 for COVID-19 treatment.
Initiated a Phase 2 study of EDP-938 in adults at high risk for RSV complications.
Began dosing in a Phase 1 study of EDP-323 for RSV treatment.
Royalty revenue for the quarter was $20.3 million.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects its current cash, cash equivalents and short-term and long-term marketable securities, as well as its continuing royalty revenue, will continue to be sufficient to meet the anticipated cash requirements of its existing business and development programs into the fourth quarter of fiscal 2024.